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Abstract
Background: Endometriosis is a clinical condition that affects up to 10% of the women of
reproductive age. Endometriosis is characterized by the presence of endometrial tissues outside
the uterine cavity and can lead to chronic pelvic pain, infertility and, in some cases, to ovarian
cancer.
Methods: In order to better understand the pathogenesis of endometriosis, we have used Serial
Analysis of Gene Expression (SAGE) to identify genes differentially in this disease by studying three
endometriotic tissues and a normal endometrium sample. Promising candidates (AXL, SHC1,
ACTN4, PI3KCA, p-AKT, p-mTOR, and p-ERK) were independently validated by
immunohistochemistry in additional normal and endometriotic tissues.
Results: We identified several genes differentially expressed between endometriosis and normal
endometrium. IGF2, ACTN4, AXL, and SHC1 were among the most upregulated genes.
Comparison of the endometriosis gene expression profiles with the gene expression patterns
observed in normal human tissues allowed the identification of endometriosis-specific genes, which
included several members of the MMP family (MMP1,2,3,10,11,14). Immunohistochemical analysis
of several candidates confirmed the SAGE findings, and suggested the involvement of the PI3K-Akt
and MAPK signaling pathways in endometriosis.
Conclusion:  In human endometriosis, the PI3K-Akt and MAPK signaling pathways may be
activated via overexpression of AXL and SHC1, respectively. These genes, as well as others
identified as differentially expressed in this study, may be useful for the development of novel
strategies for the detection and/or therapy of endometriosis.
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Background
Endometriosis is a common gynecological disorder that
affects 5–10% of women of reproductive age and that
causes dysmenorrhea, chronic pelvic pain, and infertility
[1]. Despite numerous studies on endometriosis, its etiol-
ogy and pathogenesis have not yet been fully elucidated.
The disease is characterized by the presence of endome-
trial epithelial and stromal cells outside the uterine cavity.
Biologically, these ectopic cells are quite distinct from
their eutopic counterparts. Different responses to steroid
hormones, growth factors and cytokines, chromosomal
aberrations [2-4], Loss of heterozygosity (LOH), or allelic
loss of specific chromosomal regions [5-8] have been
reported. Furthermore, especially in the case of ovarian
endometriosis, malignant transformation to ovarian can-
cer has been suggested [9,10]. On the basis of these find-
ings, ovarian endometriosis has been considered to be a
precursor lesion of ovarian carcinoma [11,12].
In the past several years, a number of microarray studies
have been performed on endometriosis tissues [13-26].
Although these studies have identified large numbers of
genes differentially expressed between endometriotic tis-
sues and eutopic endometria, few studies could identify
specific molecular pathways that are commonly involved
in the pathogenesis of this disease.
Serial analysis of gene expression (SAGE) is a high-
throughput gene expression profiling approach that can
be considered complementary to microarray approaches
[27-29]. Although SAGE is labor intensive, there are some
advantages in SAGE compared to microarray. SAGE is an
open system and does not require prior knowledge of the
genes of interest, allowing the identification of novel
genes. In addition, because SAGE is a sequencing-based
approach, this method does not have the well known lim-
itations inherent to hybridization-based assays such as
differences in hybridization capabilities of various targets
and normalization issues. Furthermore, because the gene
expression quantitation is absolute rather than relative,
data obtained by SAGE can be compared with experi-
ments from different laboratories done at different times
[30]. However, because of the labor required in the prep-
aration of the libraries, as well as the high cost of sequenc-
ing them (cost may be 5–10 times higher than
microarray), the number of samples analyzed is typically
low compared to microarray studies, and validation of the
candidates in additional samples is crucial [28,29].
Because of the differences between SAGE and microarray
approaches (i.e., sequencing vs hybrization), each tech-
nique may be better than the other at identifying certain
genes, and indeed, previous SAGE studies have been
instrumental in identifying candidate genes that had not
been found using microarray techniques [31-34]
Because of its possible role as a precursor of ovarian can-
cer, we focused this study on ovarian endometriosis. We
performed large-scale gene expression profiling of these
lesions using SAGE and compared the gene expression
profiles with those of eutopic normal endometrium.
Because of their expression pattern, SHC1, ACTN4, and
AXL, were identified as promising endometriosis-related
candidate genes, and their expression patterns were fur-
ther investigated at the protein level by immunohisto-
chemistry.
Methods
Patient Samples for SAGE
Two ovarian cysts of r-AFS (revised American Fertility
Society Classification for Endometriosis) stage IV
endometriosis and one normal eutopic endometrium
without endometriotic lesion (control) were obtained
anonymously from premenopausal women during mid to
late proliferative menstrual phase at Mercy Hospital (Bal-
timore, MD, USA). The control patient was confirmed to
have no endometriotic or other pathological lesions in the
pelvic cavity. These patients did not take any hormonal
therapy prior to their surgery. The patients gave informed
consents and the present study was approved by the NIH
Institutional Review Board and by the ethics committee of
the Mercy Hospital, Baltimore, MD, USA. Endometriotic
tissue layers were scraped from the inner wall of the cyst,
minced into small pieces, and enzymatically dissociated
by incubation with 0.25% collagenase (Sigma, St. Louis,
MO, USA) and 0.02% DNase I in phenol-red-free Dul-
becco's modified Eagle's Medium/Ham's F-12 (Invitro-
gen, Carlsbad, CA, USA) supplemented with 10% FBS
(Invitrogen) for 1 hr at 37°C. Enrichment of the endome-
triotic epithelial cells was performed by serial filtration
using 100 μm and 40 μm nylon sieves (BD Falcon, Frank-
lin Lakes, NJ, USA), and collected by back-washing the 40
μm nylon sieve onto tissue culture dishes. After incuba-
tion at 37°C for 30 minutes to allow stromal cells to
attach to the dishes, the floating endometriotic epithelial
cells in the supernatant were transferred into a T25-culture
flask and cultivated for approximately 7 days. The
endometriotic epithelial cells were harvested at 80% con-
fluence, resuspended in the Lysis/Binding Buffer of the
Dynabeads® mRNA DIRECT™ Kit (Invitrogen), immedi-
ately snap-frozen and kept at -80°C until further process-
ing. The purity of the epithelial cells was assessed by
immunopositivity of cytokeratin. A similar procedure was
used for the isolation of eutopic endometrial epithelial
cells, except that the isolation procedure started with the
mincing of the normal endometrium. Approximately, 5.0
× 105 to 1.0 × 106 cells were lysed in each sample. An
endometriotic cell line, FbEM-1, which was previously
established from ovarian and peritoneal endometriosis
[35] was also used for the present study. Total RNA of the
FbEM-1 cell line was extracted and used for SAGE.Reproductive Biology and Endocrinology 2008, 6:59 http://www.rbej.com/content/6/1/59
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SAGE
Each SAGE library was made according to the microSAGE
protocol with minor modifications. Polyadenylated
mRNA was purified on Oligo (dT)25 from the cell lysates
by using the Dynabeads® mRNA DIRECT™ Kit (Invitro-
gen) for the short-term cultivated cells, and from 10 μg of
total RNA by using the Dynabeads® mRNA Purification Kit
for the FbEM-1 cell line. cDNA was generated using the
SuperScript™ Double-Stranded cDNA Synthesis Kit (Invit-
rogen). The rest of the SAGE procedure was performed
essentially as described [36]. Colonies on the agar lawns
were picked and sequenced by Agencourt (Boston, MA).
SAGE Data analysis
Sequence data from each library were analyzed by the
SAGE software SAGE2002 to quantify tags. Tag numbers
were normalized to 200,000 to allow for direct compari-
sons of the different libraries. For further analysis, the
SAGE data was imported from the SAGE2002 software
into excel (Microsoft) spreadsheets. For the identification
of endometriosis-specific transcripts data was down-
loaded from the SAGE Genie database http://
cgap.nci.nih.gov/SAGE into excel and compared to the
endometriosis data obtained in this study. Gene expres-
sion data was obtained for the following 29 normal tis-
sues: ovarian surface epithelial cells, endometrium,
peritoneum, colon (2 libraries), prostate (2 libraries),
pancreas (2 libraries), skin, thyroid, white blood cells,
bone marrow, brain cortex, thalamus, cerebellum, stom-
ach (2 libraries), heart, kidney, liver, lung, lymph node,
breast myocytes, breast stroma cells, breast epithelial cells,
muscle (2 libraries), and vascular endothelial cells. Tags
expressed at a level of more than 20 tags/200,000 in
endometriosis and with more than 75% of their total
expression found in this tissue compared with all the
other normal tissues were considered endometriosis spe-
cific. In addition, tags that were found in more than 8 of
the 29 normal tissues were also eliminated from the list
for lack of specificity. The 20 most highly expressed genes
that satisfy those criteria were considered the best
endometriosis-specific genes. Significance and p-values
were determined using previously described approaches
[37]. A p-value of < 0.05 was accepted as statistically sig-
nificant.
Immunohistochemistry (IHC)
Eight ovarian endometriosis samples from patients with r-
AFS stage III-IV endometriosis without hormonal therapy
(age 23–52, average 41) and 5 normal endometrium spec-
imens from premenopausal women without endometrio-
sis or hormonal therapy (age 36–49, average 42) were
evaluated by IHC for the validation of SAGE data. The
control premenauposal women underwent hysterectomy
without prior hormonal therapy and were confirmed to
be free of endometriosis in the pelvic cavity and the surgi-
cally resected tissues. Among 8 cases of ovarian endome-
triosis, three cases were in the proliferative phase of the
menstrual cycle and 2 cases were in the secretory phase.
No information about the menstrual phase was available
for the remaining 3 cases of ovarian endometriomas.
Among 5 cases of normal endometrium, three cases were
in the proliferative phase of the menstrual cycle and 2
cases were in the secretory phase, respectively. Briefly,
deparafinized 5-μm sections of formalin-fixed specimens
of ovarian endometriosis and normal endometrium were
submitted to heat-induced antigen retrieval, incubated
with the specific antibodies, and processed using the
Vectastain Elite ABC Kit (Vector Laboratories, Burlingame,
CA, USA) with 3,3'-diaminobenzidine as the chroma-
togen. The sections were then counterstained with hema-
toxylin and mounted with coverslips. The following
primary antibodies were used: AXL (polyclonal, dilution
1:50, Santa Cruz Biotech., Santa Cruz, CA, USA), SHC1
(polyclonal, dilution 1:300, Santa Cruz Biotech.), phos-
pho-Erk1/2 (monoclonal, dilution 1:50 Santa Cruz Bio-
tech.), PI3KCA (polyclonal, dilution 1:50, Abgent, San
Diego, CA, USA), phospho-Akt (Ser473) (clone 736E11,
dilution 1:50, Cell Signaling Technology, Danvers, MA,
USA), phospho-mTOR (Ser 2448) (clone 49F9, dilution
1:50, Cell Signaling Technology). The antibody for
ACTN4 was kindly provided by Dr. Kazufumi Honda and
Dr. Tesshi Yamada (National Cancer Center Research
Institute, Tokyo, Japan). Staining intensity was scored as
follows: 0, none of the cells stained positively; 1, weak
staining; 2, moderate staining; and 3, strong staining. Sta-
tistical analysis was done with Student's t-test to compare
the staining intensity for each pair of normal
endometrium and endometriotic tissue samples.
Results
SAGE library construction for normal and endometriotic 
tissues
In order to characterize the gene expression patterns asso-
ciated with endometriosis, we performed SAGE on nor-
mal purified endometrial cells, two purified
endometriosis tissues, and one endometriosis cell line. To
ensure the integrity of the gene expression data, a high
emphasis was placed on obtaining pure cell populations
for our analysis. The epithelial component of the
endometriotic tissues was enriched in vitro and the purity
of the resulting cell population was confirmed by cytoker-
atin staining before performing SAGE. A similar approach
was used in the enrichment of normal endometrial cells.
The construction of SAGE libraries from the 2 endometri-
otic tissues led to high quality libraries, endom1 and
endom2, each yielding approximately 80,000 tags (Table
1). The library prepared from the endometriotic cell line
(FbEM-1) also yielded a high quality library (76,100 tags).
The library obtained from the purified normal endome-Reproductive Biology and Endocrinology 2008, 6:59 http://www.rbej.com/content/6/1/59
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trial cells, normen2, yielded fewer tags, but was still con-
sidered of acceptable quality with 19,493 tags. Multi-
dimensional scaling (MDS) analysis showed that overall,
the gene expression profiles were extremely similar
between the various endometriosis tissues (and normal
endometrium) when compared with other tissues
included as controls, such as colon, ovarian, and perito-
neal tissues (Fig. 1A).
Gene expression profiles in endometriosis
Cluster analysis was performed on the SAGE libraries and
differentially expressed genes were identified (Fig. 1B).
Table 2 shows the top 20 upregulated and downregulated
genes in endometriosis compared to normal endometrial
cells. Overall, a much larger number of genes were highly
upregulated as opposed to downregulated. For example,
we found 53 genes that were elevated more than 100-fold,
but only 2 genes downregulated by at least 100-fold.
Among the highly elevated genes, we found several
involved in signaling such as IGF2,  ACTN4,  AXL, and
SHC1. The list of downregulated genes (Table 2) con-
tained several myosin and actin related genes (MYL6,
ACTG1, MRLC2).
In addition, further analysis using the SAGE genie data-
base, allowed the identification of genes that are highly
specific for endometriosis. SAGE libraries for 29 normal
tissues (see "methods" section for the list) were obtained
from the SAGE Genie database and compared to the
endometriosis libraries constructed for this report. Tags
that are highly specific for endometriosis tissues are
shown in Table 3. Only tags expressed at a level of more
than 20 tags/200,000 in endometriosis and with more
than 75% of their total expression found in this tissue
were selected. In addition, tags that were found in more
than 8 of the 29 normal tissues were also eliminated from
the list for lack of specificity. This set of criteria allowed us
to identify 20 genes that are highly specific for endometri-
osis. Interestingly, MMPs are prominently represented,
with 6 family members (MMP1, 2, 3, 10, 11, 14) present
among the top 20 endometriosis-specific genes.
Validation of SAGE data by immunohistochemistry of 
selectedcandidates
AXL, SHC1, and ACTN4, all shown to be overexpressed in
endometriotic epithelial cells by SAGE, were selected for
IHC validation. IHC analysis demonstrated that these
genes were significantly overexpressed at the protein level
in ovarian endometriotic tissues in comparison to normal
endometrium for both epithelial and stromal cells (Fig. 2,
Table 4). Among the normal endometrium samples, weak
to moderate staining of these proteins was observed in
those from the proliferative phase, but weak staining was
observed in the secretory phase. On the other hand, mod-
erate to strong staining was consistently seen in ovarian
endometriosis regardless the menstrual phase (Table 4).
Although information about the menstrual phase of three
ovarian endometriosis samples was not available, data
from the other samples demonstrated that the staining
intensity of these proteins in endometriosis was consist-
ently positive regardless of the menstrual phase. Staining
of these proteins in normal endometrium was weak and
only positive during the proliferative phase.
Next, we investigated the possibility that downstream
pathways in which AXL and SHC1 are involved, PI3K/Akt
and MAPK respectively, may be activated in endometrio-
sis. The immunohistochemical analysis for p-ERK,
PIK3CA, p-AKT, and p-mTOR demonstrated that all 4 pro-
teins were significantly overexpressed in ovarian endome-
triomas lining cells compared with normal endometrium
(Fig. 2, Table 4). These findings strongly suggest that both
MAPK and PI3K/AKT pathways are constitutively acti-
vated in ovarian endometriosis.
Discussion
In this report, we have used SAGE to determine gene
expression patterns of ovarian endometriosis and to iden-
tify genes differentially expressed in this disease. While
other endometriosis gene expression profiling studies
have been published, our study is unique for two main
reasons. First, the use of SAGE allows an unbiased view of
gene expression and is not limited to the genes present on
an array. Moreover, it provides an absolute quantitation
of gene expression levels, which can then be compared to
results from other studies, or other tissues present in pub-
lic databases. Second, we have put high a high emphasis
on isolating pure epithelial endometriotic cells, thus
ensuring that the gene expression profiles are representa-
tive of the cell type of interest as opposed to representing
a mixture of multiple cell types. The endometriosis SAGE
libraries obtained here are of extremely high quality and
are comprised of approximately 80,000 tags, allowing the
detection of genes expressed at relatively low levels. While
the complexity of the normal endometrium library was
lower, possibly due to the relative difficulty in isolating
epithelial endometrial cells in high number, the library
was still quite useful with approximately 20,000 tags. It is
important to note the relatively low, although typical,
number of samples studied by SAGE for this study. The
number of samples for SAGE analysis is typically smaller
than that used for microarray for various reasons related
Table 1: SAGE libraries information
Library name Sequences Total tags Total genes >1*
Normal endometrium 2016 19493 10089 2193
endom1 2688 80783 20727 7200
endom2 2784 77846 24329 7394
FbEM-1 2688 76100 25652 7274
*number of tags found more than once.Reproductive Biology and Endocrinology 2008, 6:59 http://www.rbej.com/content/6/1/59
Page 5 of 13
(page number not for citation purposes)
Serial Analysis of gene expression of endometriosis Figure 1
Serial Analysis of gene expression of endometriosis. A. 2D MDS plot shows that tissues of related origin cluster 
together. Endometrium and endometriosis libraries (NORMEN, ENDOM1, ENDOM2 and FbEM-1) are indicated in red, ovar-
ian tissues (normal ovarian surface epithelial cell lines: IOSE and HOSE, ovarian cancer tissues: ES2, OVT6, OVT7, and OVT8) 
in dark blue, normal peritoneum (NPERITO) and malignant mesothelioma (MMESO) in light blue, and colon tissues (normal 
colon epithelium: NC1 and NC2, colon cancer tissues: Tu98 and Tu 102) in green. B. Clustering analysis of tags level in the 
three endometriosis libraries (endom1, endom2 and FbEM-1). The levels are relative to the expression in normal 
endometrium. Areas consisting of tags consistently elevated, decreased, or unchanged are shown above the heat map.
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to the complexity and cost of constructing SAGE libraries
[28,29]. On the other hand, the accuracy and reproduci-
bility of the data has been shown to be extremely high
[29], and the low number of primary samples studied by
SAGE is typically complemented by validation on addi-
tional samples using independent techniques.
The issue of cell purity is crucial. While some microarray
studies have used whole bulk endometriotic tissues as
starting material, others have taken advantage of laser cap-
ture microdissection (LCM) for endometriotic cell enrich-
ment. However, LCM leads to RNA of insufficient quality
and quantity for SAGE analysis. For these reasons, we used
short-time cultivated primary epithelial endometriotic
and endometrial cells as starting material. While we
focused our study on the epithelial component of
endometriosis, it is important to note that there are sev-
eral reports that suggest a role for the endometriotic
stroma in the pathogenesis of endometriosis, and the bio-
logical aberrations of the endometriotic stromal cells may
Table 2: Genes differentially expressed in endometriosis
Tag_Sequence symbol gene name endom1 endom2 FbEM-1 normen2 Fold
Elevated
CCAGTGGCCC RPS9 Ribosomal protein S9 64 77 154 0 590
CGAGGGGCCA ACTN4 Actinin, alpha 4 108 50 98 0 512
CTTGGGTTTT IGF2 Insulin-like growth factor 2 (somatomedin A) 28 193 16 0 474
GTATGGGCCC CHI3L1 Chitinase 3-like 1 (cartilage glycoprotein-39) 22 160 10 0 384
GCTGAACGCG CEBPB CCAAT/enhancer binding protein (C/EBP) 29 100 15 0 288
CGCAGTGTCC ATP6V0C ATPase, H+ transporting, lysosomal 16kDa 53 41 31 0 250
TGAAGTTATA ITGB1 Integrin, beta 1 (fibronectin receptor) 39 37 48 0 248
AGCTACCGGG EFEMP2 EGF-containing fibulin-like ECM protein 2 55 11 54 0 240
CGGCTGGTGA PSMB1 Proteasome (prosome, macropain) 32 32 52 0 232
GTGCCCTGTT NCKAP1 NCK-associated protein 1 42 46 20 0 216
TTGCCCCCGT AXL AXL receptor tyrosine kinase 42 51 14 0 214
GCAGTCGCTT DYNLRB1 Dynein, light chain 40 37 28 0 210
CAGCTGGGGC PTBP1 Polypyrimidine tract binding protein 1 27 26 52 0 210
GCCACAGTAC DKFZP586H2123 Regeneration associated muscle protease 42 42 16 0 200
GCCCCGAGCC REEP5 Receptor accessory protein 5 18 34 43 0 190
ACCCCCCCGC JUND Jun D proto-oncogene 35 21 38 0 188
GAAACAAGAT PGK1 Phosphoglycerate kinase 1 19 28 44 0 182
GAGGGGAAAC SHC1 SHC (Src homology 2 domain containing) 40 32 15 0 174
GCCAACAACG NNMT Nicotinamide N-methyltransferase 28 15 42 0 170
TTGCCCAGCA CEECAM1 Cerebral endoth. cell adhesion molecule 1 33 32 17 0 164
Decreased
GGGCGGAGCT SMARCC2 Myosin, light chain 6 0 0 0 68 136
TAATTTTGAA SNHG5 Small nucleolar RNA host gene 5 0 0 0 50 100
TCCCTATGCT Hs.689482 CDNA FLJ45874 0 0 0 40 80.0
AAGTGTGACG ACTG1 actin, gamma 1 0 0 0 36 72.0
AAATTTTAAA HP1BP3 Heterochromatin protein 1, binding prot 3 0 0 0 31 62.0
TGGTGTTTGG PPIE Peptidylprolyl isomerase E 0 0 0 27 54.0
GGGGATCGGT MRLC2 Myosin regulatory light chain MRLC2 0 0 0 22 44.0
TGGTGTGTGC Hs.684687 cDNA clone ZD94H12 0 0 0 22 44.0
TCCCTATAAA no match Undefined 0 0 0 18 36.0
AGGACAGCAA MYL6 Myosin, light chain 6 0 1 0 40 27.0
TCCCTAGCCC no match Undefined 0 0 1 40 27.0
GCTTATAAAA HINT1 Histidine triad nucleotide binding protein 1 0 0 0 13 26.0
TAAACTGTTT RPS14 Ribosomal protein S14 0 0 0 13 26.0
TATGTGTTTT PAPSS2 3'-phosphoadenos 5'-phosphosulf synth 2 0 0 0 13 26.0
TCCCTTTTAA B3GNT5 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 5
0001 3 2 6 . 0
TTGAAAATTA ANXA2 Annexin A2 0 0 0 13 26.0
TTGGAACAAT no match Undefined 0 0 0 13 26.0
TAGACCCCTT GAPDH Glyceraldehyde-3-phosph dehydrogenase 1 0 0 36 24.0
AAAGGAGAGA NUCB2 Nucleobindin 2 0 0 0 9 18.0
AAGCCTGTAG CAMLG Calcium modulating ligand 0 0 0 9 18.0
The numbers shown represent the number of tags detected in the indicated libraries per 200,000 total tags. "Fold" indicates the ratio of tags 
detected in endometriosis vs normen2 (for elevated tags) or normen2 vs endometriosis (for decreased tags). A count of zero (0) tag indicates 
absence of detection (out of 200,000 tags), not necessarily complete absence of expression in the corresponding tissue.Reproductive Biology and Endocrinology 2008, 6:59 http://www.rbej.com/content/6/1/59
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be also related, at least indirectly, to malignant transfor-
mation of endometriosis to ovarian cancers. However, as
a first step in our endometriosis SAGE analysis, we chose
to focus on the epithelial component of endometriosis.
Endometriosis, an ectopic lesion of endometrium, has
been recognized as a precancerous condition for endome-
trioid and clear cell ovarian carcinomas [12]. Using MDS,
we first show that the gene expression patterns exhibited
by the endometriosis samples are very similar to each
other and to normal endometrium, but fairly different
from epithelial ovarian cancer. This suggests that, if
endometriosis can indeed progress to ovarian cancer,
extensive changes in genes expression and signaling path-
ways must occur for this progression to occur. However, it
is important to note that the ovarian carcinomas present
in the SAGE database and used for this comparison are of
serous histology and that endometriosis is not believed to
commonly arise from this ovarian cancer subtype. It is
possible that endometrioid and clear cell carcinomas
would be much more similar to endometriosis than ovar-
ian serous carcinoma and previously published evidence
would suggest that it might be the case [12]. Clearly, SAGE
analysis of clear cell and endometrioid ovarian cancer
would be required to resolve this issue. In any case, the
data presented here shows that endometriosis tissues are
different from serous ovarian carcinoma tissues in terms
of overall gene expression, although it certainly remains
possible that certain crucial molecular pathways may be
shared between these diseases.
Because SAGE data can be compared between studies and
laboratories, we decided to use the large SAGE genie data-
base to identify genes specific to endometriosis by looking
for those that are overexpressed in this disease, but that
tend to be low in most normal human tissues. We believe
that these endometriosis-specific genes may represent use-
ful targets for therapy, as they may be targeted with mini-
mal damage to normal tissues. Using strict criteria for the
identification of these genes, we found a number of genes
whose expression was relatively specific to the endometri-
otic tissues studied (Table 3). Remarkably, several MMP
genes (MMP1,2,3,10,11,14) were found overexpressed
and specific for endometriosis, possibly providing a bio-
logical explanation for the propensity of these cells to
invade the surrounding tissues. Consistent with these
findings, upregulation of MMP1, 2, 3 has previously been
reported in endometriosis [38-42]. MMP expression may
be the result of the inflammation associated with
endometriosis [43]. In any case, these findings suggest
that MMP inhibitors may provide another therapeutic
strategy in controlling the spread of endometriosis.
Comparison of gene expression between endometriosis
and normal endometrium allowed the identification of a
large number of differentially expressed genes. Genes
identified as differentially expressed by various previous
studies exhibit little overlap with each other and with our
current study [13-26]. This may be due to a number of rea-
sons, including differences in sample collection or
processing and differences in the profiling platforms. For
Table 3: Endometriosis-specific genes
Tag_Sequence Neg. Tags in endom % in endo Symbol Gene name
GAGCCAGGCT 27 1249 96.6 MMP3 Matrix metallopeptidase 3
TGTCATCACA 22 320 76.3 LOXL2 Lysyl oxidase-like 2
TGCAGTCACT 26 317 88.6 MMP1 Matrix metallopeptidase 1
TGCAATAGGT 26 265 90.3 MMP10 Matrix metallopeptidase 10
GCCAGGTGGC 22 244 81.8 MMP2 Matrix metallopeptidase 2
GTATGGGCCC 24 183 88.7 CHI3L1 Chitinase 3-like 1
CCGGGGGAGC 27 158 87.5 COL1A1 Collagen, type I, alpha 1
CAGGAGACCC 28 144 98.1 MMP11 Matrix metallopeptidase 11
CGGGGCGGGG 28 67 83.1 KISS1 KiSS-1 metastasis-suppressor
CCCGCCAGTG 27 59 85.6 ITGA11 Integrin, alpha 11
CTAAGTAGAG 23 59 56.7 undefined Undefined
GTGCTCAGTG 28 49 78.2 PXDN Peroxidasin homolog (Drosophila)
GTTTTATGCG 27 48 86.8 DCBLD1 Discoidin, CUB, LCCL domain containing 1
ACAGAGGGGC 28 47 96.2 ABBA-1 Actin-bundling with BAIAP2 homology
CAGTCAATAT 25 43 74.5 FLJ11041 FLJ11041
GTACCGGGGA 27 36 80.5 MMP14 Matrix metallopeptidase 14
GCTAGACGCG 28 29 86.4 FOXL2 Forkhead box L2
CTGTGGTTAC 26 24 77.7 SLC39A13 Solute carrier family 39, member 13
CACACAAACA 27 23 75.0 TWF1 Twinfilin, actin-binding protein, homolog 1
CAGGCCAACC 28 20 91.6 RSU1 Ras suppressor protein 1
"Neg." indicates the number of libraries without detectable expression of the corresponding tags (out of 29 total libraries). "Tag in endom" and "% 
in endo" indicate the number of tags in endometriosis (per 200,000 total tags), and the percentage of these tags found in endometriosis compared 
to all the tissues, respectively.Reproductive Biology and Endocrinology 2008, 6:59 http://www.rbej.com/content/6/1/59
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example, here, we have used eutopic endometrium with-
out endometriosis as normal control tissues. Other stud-
ies have used eutopic endometrium from patients with
endometriosis as controls, although this clearly may not
be ideal. In spite of these differences, we do identify genes
that have previously been found in other studies. For
example, we show Integrin β1 and Dynein to be upregu-
lated in endometriosis and Matsuzaki and colleagues also
documented upregulation of those genes in eutopic
endometrium of secretory menstrual phase with deep
endometriosis [17]. We also demonstrate upregulation of
SHC1 and activation of its downstream pathway, MAPK
pathway (discussed below). Activation of the MAPK path-
way in endometriosis has also been suggested following
the observation that PDGFR, PDGF, and RAF1, are highly
elevated in this disease [18]. Furthermore, upregulation of
SOS has been demonstrated in eutopic endometrium of
late-secretory phase with deep endometriosis [17].
It is well accepted that cell motility and invasion are
involved in the pathogenesis of endometriosis, and these
function may be related to the oncogenic potential of
endometriosis. The present SAGE study reveals that some
genes related to cell motility and invasion are indeed
Table 4: IHC staining summary of candidate proteins.
Protein Cells Localization Endometriosis (n = 8) Endometrium (n = 5) P value
AXL Epithelial cells Nucleus 1.4 ± 0.74 0.0 0.00061
Cytoplasm 2.5 ± 0.53 1.2 ± 1.1 0.027
Stromal cells Nucleus 1.3 ± 0.71 0.0 0.00087
Cytoplasm 1.5 ± 0.53 0.0 0.000048
SHC1 Epithelial cells Nucleus 1.3 ± 0.46 0.80 ± 0.84 0.16
Cytoplasm 2.0 ± 0.53 1.2 ± 0.55 0.043
Stromal cells Nucleus 1.4 ± 0.74 0.20 ± 0.45 0.0023
Cytoplasm 1.5 ± 0.76 0.40 ± 0.55 0.0059
ACTN4 Epithelial cells Nucleus 1.3 ± 0.71 0.60 ± 0.89 0.11
Cytoplasm 2.9 ± 0.35 1.6 ± 0.55 0.0017
Stromal cells Nucleus 1.1 ± 0.99 0.20 ± 0.45 0.022
Cytoplasm 2.1 ± 0.99 0.40 ± 0.55 0.0022
PIK3CA Epithelial cells Nucleus 1.9 ± 0.64 0.40 ± 0.55 0.00069
Cytoplasm 2.5 ± 0.53 1.4 ± 0.55 0.0034
Stromal cells Nucleus 1.6 ± 0.52 0.20 ± 0.45 0.00021
Cytoplasm 1.5 ± 0.53 0.20 ± 0.45 0.00042
p-AKT Epithelial cells Nucleus 1.4 ± 0.74 0.0 0.00061
Cytoplasm 2.1 ± 0.45 0.80 ± 0.45 0.00058
Stromal cells Nucleus 1.4 ± 0.74 0.0 0.00061
Cytoplasm 1.6 ± 0.74 0.0 0.00023
p-mTOR Epithelial cells Nucleus 1.8 ± 0.46 0.60 ± 0.55 0.0026
Cytoplasm 2.5 ± 0.53 1.6 ± 0.55 0.0092
Stromal cells Nucleus 1.4 ± 0.52 0.20 ± 0.45 0.00081
Cytoplasm 1.3 ± 0.71 0.0 0.00078
p-Erk Epithelial cells Nucleus 0.63 ± 0.74 0.0 0.025
Cytoplasm 2.5 ± 0.76 1.6 ± 0.55 0.016
Stromal cells Nucleus 0.50 ± 0.53 0.0 0.017
Cytoplasm 1.0 ± 0.53 0.20 ± 0.45 0.0079Reproductive Biology and Endocrinology 2008, 6:59 http://www.rbej.com/content/6/1/59
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Immunohistochemical studies of candidates Figure 2
Immunohistochemical studies of candidates. Representative immunohistochemical staining of normal endometrium and 
endometriosis tissues for the indicated proteins (AXL, SHC1, ACTN4, PI3KCA, p-AKT, p-mTOR, and p-ERK) are shown. The 
candidates shown exhibit increased expression of both epithelial and stromal cells of the endometriotic tissues compared to 
normal endometrial tissues.
SHC1
ACTN4
p-AKT
p-ERK
Endometrium Endometriosis
AXL
PI3KCA
p-mTORReproductive Biology and Endocrinology 2008, 6:59 http://www.rbej.com/content/6/1/59
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deregulated. ACTN4 and Dynein are upregulated, whereas
MYL6, ACTG1 and MRLC2 are downregulated (Table 2).
Several MMPs such as MMP1, MMP2, MMP 3, MMP10,
MMP 11, and MMP 14 are identified as endometriosis-
specific genes (Table 3). Furthermore, the proto-onco-
genes AXL, SHC1, and JUND are elevated in endometrio-
sis (Table 2).
Of particular interest among the differentially expressed
genes are those that are involved in well-known signaling
pathways that could be inhibited using available drugs.
AXL, a member of Tyro3/AXL/Mer (TAM) receptor tyro-
sine kinase (RTK) family, was shown to be upregulated in
endometriosis by SAGE and IHC in the present study.
GAS6, a ligand of TAM family, was also found to be upreg-
ulated in two of three endometriotic SAGE libraries com-
pared with eutopic endometrium. Overexpression of both
AXL and GAS6 in ovarian endometriosis has previously
been demonstrated using RT-PCR analysis and IHC [44].
Co-overexpression of AXL with Gas6 has also been
reported in several types of tumors including ovarian can-
cer [45], and may therefore have an important role in
uncontrolled cell growth/proliferation. Because the PI3K-
Akt signaling pathway is a well known downstream effec-
tor of the GAS6/AXL system, we investigated some of the
critical components of the PI3K-Akt pathway (PIK3CA, p-
Akt, and p-mTOR) in endometriotic tissues using IHC.
Similar to what we observed for AXL, the PI3K-Akt signal-
ing pathway was either inactive or weakly active in eutopic
endometrium, whereas it was consistently activated in
endometriosis. Therefore, it is possible that overexpres-
sion of AXL and GAS6 is a main cause for the activation of
the PI3K-Akt pathway in endometriosis. As the PI3K-Akt
pathway is involved in cell survival, proliferation, and
migration, its activation through GAS6/AXL may be a
common central biological event during the pathogenesis
of endometriosis. Indeed, it was recently shown that acti-
vation of K-Ras or inactivation of Pten in mouse ovarian
surface epithelial cells can lead to endometriosis-like
lesions in the ovary [46]. Since both K-ras and Pten are
involved in the PI3K-Akt pathway, alteration of either of
these genes could theoretically activates this signaling
pathway (Fig. 3).
Similar to what we observed for AXL, SHC1 was found
consistently elevated in the studied endometriotic sam-
ples. The transforming activity of SHC1 has been estab-
lished [47], and its overexpression has been reported in
neoplasias such as breast, gastric and hepatocelullar carci-
nomas [48-50]. SHC1 is an adaptor protein that mediates
signal transduction in the MAPK pathway, and that can
also interact with the p85 regulatory subunit of PI3K.
SHC1 could therefore contribute the activation of MAPK
and/or the activation of the PI3K-Akt pathway in these
tumors. In the current study, we report elevated levels of
p-ERK in endometriosis, suggesting activation of the
MAPK pathway. Interestingly, this pathway was also
shown to be activated in ovarian endometrioid adenocar-
cinoma derived from endometriosis in a mouse model
[46]. The MAPK pathway is therefore constitutively acti-
vated in both human endometriosis and in the mouse
endometriosis model, and the overexpression of SHC1 is
an intriguing mechanism for the activation of this path-
way in human endometriosis (Fig. 3). Although, the com-
parison of gene expression profiles between
endometriosis and normal endometrium was done for
the proliferative phase, AXL, SHC1, and ACTN4 (dis-
cussed below) were also overexpressed during secretory
phase in ovarian endometriosis. Continual overexpres-
sion of these genes may stimulate cell growth without hor-
monal stimulation. It is worth noting that these results
were obtained through analysis of stage III and IV
endometriosis samples. It will be important to extend
these findings to early stage endometriosis in order to
determine whether these genes may also be useful as early
detection markers or therapeutic targets for the prevention
of endometriosis development.
ACTN4, which we find strongly expressed in the endome-
triotic samples, is another candidate gene possibly
involved in the pathogenesis of endometriosis. ACTN4 is
a non-muscular type of alpha-actinin, a family of actin-
bundling protein. Enhanced cytoplasmic expression of
ACTN4 is related to increased cell motility and invasion
[51] and ACTN4 has recently been implicated in breast,
lung, colorectal and ovarian cancers [52-54]. Interestingly,
enhanced cytoplasmic expression of ACTN4 is observed
in about 60% of endometrioid and clear cell ovarian can-
cers [54], both of which have been suggested to possibly
arise, at least in some cases, from endometriosis. Further-
more, since PI3K can control nuclear translocation of
ACTN4, activation of the PI3K-Akt pathway in endometri-
osis may facilitate enhanced cytoplasmic expression of
ACTN4, and may contribute the cell motility and invasion
observed in endometriosis.
As discussed above, either oncogenic activation of K-ras or
biallelic losses of Pten of ovarian surface epithelium
causes endometriosis-like-lesions in the mouse ovary
[46]. However, in human endometriosis, no KRAS muta-
tions have been found [55], and alterations of PTEN have
been found in only 20% of the cases [8]. As overexpres-
sion of AXL and SHC1 theoretically activates both PI3K-
Akt and MAPK pathways, dysregulation of these genes in
human endometriosis may correspond to oncogenic acti-
vation of K-ras or biallelic losses of Pten in the mouse
model of the disease. Receptor Tyrosine Kinases (RTKs)
are known to potentially activate both the PI3K/Akt and
MAPK pathways. However, except for a report showing an
increase in c-Met (RTK) and HGF (ligand) in endometrio-Reproductive Biology and Endocrinology 2008, 6:59 http://www.rbej.com/content/6/1/59
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sis [56], there has been little evidence that RTK are overex-
pressed or activated in this disease.
Conclusion
Our data show that AXL and SHC1 are differentially
expressed in endometriosis implicating the PI3K and
MAPK pathways in this disease. AXL may represent a
promising new therapeutic target for endometriosis. For
example, the use of an AXL-extracellular domain or an
AXL dominant-negative receptor mutant for endometrio-
sis treatment may be advantageous compared to conven-
tional therapies such as GnRHa and Danazol. AXL, as well
as the other endometriosis-related genes identified in this
study, may therefore represent exciting new candidates for
the detection and therapy of this disease.
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Schematic representation of molecular pathways possibly involved in the pathogenesis of endometriosis Figure 3
Schematic representation of molecular pathways possibly involved in the pathogenesis of endometriosis. The 
overexpression of SHC1, ACTN4, and AXL observed in the endometriotic samples may lead to the activation of the PI3K and 
MAPK signaling pathways in human endometriosis. The purple arrows indicate the genes which were shown to be overex-
pressed in human endometriosis by the SAGE and IHC of the present study. In addition, the red arrows indicate the genes 
which are activated or inactivated in the mouse model of endometriosis. PIK3CA encodes p110 alpha catalytic subunit of PI3K.
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